Use of imidazole derivatives as MDR modulators

(19)

(11)

EP 2 082 740 A3

(12)	EUROPEAN PATENT APPLICATION

(88)	Date of publication A3:
	26.08.2009 Bulletin 2009/35

(43)	Date of publication A2:
	29.07.2009 Bulletin 2009/31

(21)	Application number: 09004628.5

(22)	Date of filing: 06.07.1998

(51)

International Patent Classification (IPC):

A61K 31/4164^(2006.01)
A61K 31/42^(2006.01)
A61K 31/428^(2006.01)
A61K 31/497^(2006.01)
A61K 31/496^(2006.01)

A61K 31/4178^(2006.01)
A61K 31/423^(2006.01)
A61K 31/454^(2006.01)
A61K 31/5377^(2006.01)
A61P 35/00^(2006.01)

(84)	Designated Contracting States:
	DE FR GB

(30)

Priority:

09.07.1997 US 890911

(62)	Application number of the earlier application in accordance with Art. 76 EPC:
	98934267.0 / 0999835

(71)	Applicant: Taiji Biomedical, Inc.
	Menlo Park, CA 94025 (US)

(72)	Inventors:
	Mjalli, Adnan Louisville, KY 40241 (US) Zhang, Chengzhi Carlsbad, CA 92009 (US)

(74)	Representative: Sauvage, Renée
	Cabinet Sauvage 65, Boulevard Soult 75012 Paris 75012 Paris (FR)

(54)	Use of imidazole derivatives as MDR modulators

(57) The invention relates to the use of imidazole derivatives having formula (I)

or their pharmaceutically acceptable salts for treating tumor cells and for increasing the sensitivity of multidrug resistant tumor cells to antitumor chemotherapeutic agents.

Search report